AlzChem Group (ACT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
2 Dec, 2025Executive summary
Achieved record sales of EUR 554 million in 2024, up 3% year-over-year, with specialty chemicals driving growth and now representing 63% of total sales and nearly 90% of earnings contribution.
EBITDA reached EUR 105.3 million, a 29% increase year-over-year, surpassing the EUR 100 million milestone; net income hit a record EUR 54.2 million, up 56%.
Dividend proposal of EUR 1.80 per share, a 50% increase, with a payout ratio expected to remain at the lower end of 30-35% due to ongoing CapEx needs.
Received a platinum EcoVadis rating for sustainable corporate governance, placing in the top 1% for ESG, and published a comprehensive CSRD-compliant non-financial report.
Major investment project of approximately EUR 140 million underway for Nitroguanidine expansion, with construction starting in Germany and US site search ongoing.
Financial highlights
Specialty chemicals segment sales grew 9% to nearly EUR 350 million, with EBITDA up 28% to EUR 94 million and margin rising to 27%.
Group EBITDA margin improved to 19% from 15.1% last year.
Earnings per share increased to EUR 5.31 from EUR 3.40.
Operating cash flow rose 45% to EUR 105 million; net financial position shifted from EUR 46 million net debt to EUR 12.9 million net assets.
Equity increased to EUR 207 million, equity ratio at 43%; cash and cash equivalents rose to EUR 61.5 million.
Outlook and guidance
2025 sales expected to reach EUR 580 million (+5%), EBITDA to EUR 113 million (+7%), driven by further volume growth in specialty chemicals, especially Creapure, Creamino, and Nitroguanidine.
Custom manufacturing volumes and prices anticipated to recover as destocking effects subside and order intake improves.
CapEx for 2025 projected at around EUR 100 million, before EU subsidies.
Free cash flow expected to remain positive in 2025, supported by customer prepayments for nitroguanidine expansion.
Assumes stable global economy, high electricity prices, and no major geopolitical disruptions.
Latest events from AlzChem Group
- Specialty chemicals leader targets €600 million sales in 2026, driven by innovation and expansion.ACT
Company presentation27 Feb 2026 - Specialty chemicals drove record margins and growth, with major capacity expansions underway.ACT
H2 202527 Feb 2026 - Specialty Chemicals drove H1 2025 growth and margins, supporting a strong outlook despite headwinds.ACT
Q2 20253 Feb 2026 - EBITDA up 36% and net income up 66% as Specialty Chemicals drive robust, grant-backed growth.ACT
Q3 202416 Jan 2026 - EBITDA up 10% and margin at 18.9% as Specialty Chemicals drive growth and 2025 outlook is confirmed.ACT
Q1 20253 Dec 2025 - Specialty Chemicals drove robust sales, margin, and profit growth; 2025 outlook reaffirmed.ACT
Q3 20254 Nov 2025 - EBITDA and net income surged in H1 2024, prompting a raised full-year outlook above €100M.ACT
H1 202413 Jun 2025